Bottero E, Benvenuti E, Ferriani R, Manassero E, Re G, Barbero R
Endovet Group, Viale V. Marronaro, 130 - 00128 Roma, RM, Italy.
San Francesco Veterinary Hospital, Via Newton, 2 - 20148 Milano, MI, Italy.
Vet Anim Sci. 2020 Jul 21;10:100138. doi: 10.1016/j.vas.2020.100138. eCollection 2020 Dec.
Despite the lack of evidence of the ability to suppress gastric acid secretion in dogs, ranitidine (RT) is often used to control clinical signs in dogs with acute vomiting even if the way it happens it is still largely unknown. The aim of this study was thus to evaluate the therapeutic effect of ranitidine on H2 receptors in dogs with acute vomiting. To investigate the RT activity a preliminary study was performed in dogs which underwent gastroscopy analyses, demonstrating that the level of H2R observed in the serum and gastric wall tissue was the same [1.473(1.30; 1.79) ng/ml and 1.498 (1.33; 1.85) ng/ml, respectively]. After that H2R levels in the serum of 22 healthy dogs (Group 1) and in a group of 22 dogs with acute vomiting (Group 2) were compared both before (T0), after 7-10 days (T1) of 2 mg/kg twice a day ranitidine administration and after 11 days since the drug was discontinued (T2). Significant differences (<0.001) were detected between the level of circulating H2R among Group 1: 0.41 ng/ml (0.28;0.54) and Group 2: 2.27 ng/ml (2.11;2.49) at T0. In Group 2, no difference in the level of H2R was detected in samples collected at T0 compared to those at T1 [T1: 2.32 ng/ml (2.14; 2.49)] and T2 [T2: 2.30 ng/ml (1.99;2.69)]. In Group 2 all patients but one displayed remission of symptoms attributable to inflammatory gastropathy at the first withdrawal (T1: 7-10 days), while at the second withdrawal (T2: after 21 days), remission was detected in all dogs. Our preliminary hypothesis is that the clinical efficacy of ranitidine is related to the greater expression of H2 receptors in patients with acute vomiting. This increased expression may be due to continuous pathological stimulus at the gastric level. Further studies with a wider population are needed to better investigate the activity of RT in dogs with acute onset of vomiting.
尽管缺乏雷尼替丁（RT）在犬类中抑制胃酸分泌能力的证据，但即使其作用方式仍 largely 未知，雷尼替丁（RT）仍常被用于控制急性呕吐犬的临床症状。因此，本研究的目的是评估雷尼替丁对急性呕吐犬 H2 受体的治疗效果。为研究 RT 的活性，对接受胃镜分析的犬进行了初步研究，结果表明血清和胃壁组织中观察到的 H2R 水平相同[分别为 1.473(1.30; 1.79) ng/ml 和 1.498 (1.33; 1.85) ng/ml]。之后，比较了 22 只健康犬（第 1 组）和 22 只急性呕吐犬（第 2 组）血清中 H2R 水平，在每天两次给予 2mg/kg 雷尼替丁 7 - 10 天（T1）之前（T0）、之后以及停药 11 天（T2）之后。在 T0 时，第 1 组循环 H2R 水平为 0.41 ng/ml(0.28;0.54)，第 2 组为 2.27 ng/ml(2.11;2.49)，两组之间检测到显著差异（<0.001）。在第 2 组中，与 T1 时采集的样本[T1: 2.32 ng/ml(2.14; 2.49)]和 T2 时采集的样本[T2: 2.30 ng/ml(1.99;2.69)]相比，T0 时采集的样本中 H2R 水平没有差异。在第 2 组中，除一只犬外，所有犬在首次停药时（T1: 7 - 10 天）因炎症性胃病引起的症状均缓解，而在第二次停药时（T2: 21 天后），所有犬均检测到缓解。我们的初步假设是雷尼替丁的临床疗效与急性呕吐患者中 H2 受体的更高表达有关。这种表达增加可能是由于胃水平的持续病理刺激。需要对更广泛的人群进行进一步研究，以更好地研究 RT 在急性呕吐犬中的活性。
